Puretech Health PLC (PRTC) Given “Buy” Rating at Peel Hunt
Several other analysts have also recently issued reports on PRTC. Liberum Capital reiterated a buy rating and issued a GBX 248 ($3.21) target price on shares of Puretech Health PLC in a research note on Wednesday, May 10th. N+1 Singer reiterated a buy rating and issued a GBX 256 ($3.31) target price on shares of Puretech Health PLC in a research note on Tuesday, May 16th. Finally, Jefferies Group LLC reiterated a buy rating and issued a GBX 255 ($3.30) target price on shares of Puretech Health PLC in a research note on Friday, June 9th. Five research analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus target price of GBX 246.80 ($3.19).
Shares of Puretech Health PLC (LON PRTC) opened at 137.50 on Tuesday. Puretech Health PLC has a 52-week low of GBX 110.00 and a 52-week high of GBX 170.00. The firm’s market capitalization is GBX 319.98 million. The stock has a 50 day moving average of GBX 133.48 and a 200-day moving average of GBX 121.39.
Puretech Health PLC Company Profile
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Stock Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related stocks with our FREE daily email newsletter.